Mate, it was a risky stock before Novartis got on board. This stock will be fine for years to come and now has the monetary backing to really progress trials in an extensive and compelling manner. I've not done enough research on the heart trials preferring to bow to others on here, but if the secondary endpoint of 60% reduction in mortality is not compelling enough for the FDA, it will be for Novartis to pump more money in....
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-187
-
- There are more pages in this discussion • 836 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.043(3.15%) |
Mkt cap ! $1.615B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.496M | 2.534M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 89022 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 28546 | 6 |
View Market Depth
| Last trade - 15.49pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |